Skip to main content
SpringerLink
Log in

Combination therapy with ONO-KK1-300-01, a cathepsin K inhibitor, and parathyroid hormone results in additive beneficial effect on bone mineral density in ovariectomized rats

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

This study examined the effects of a novel cathepsin K inhibitor, ONO-KK1-300-01 (KK1-300), used concurrently with parathyroid hormone (PTH) in ovariectomized (OVX) rats. KK1-300 (3 mg/kg, twice daily), alendronate (1 mg/kg, once daily) or vehicle were orally administered to OVX rats for 56 days, starting the day after ovariectomy, followed by combination treatment with or without PTH (3 μg/kg, subcutaneously three times a week) for another 28 days. OVX control animals exhibited a significant increase in both bone resorption (urinary deoxypyridinoline; DPD) and formation markers (serum osteocalcin) as well as microstructural changes associated with decreased bone mineral density (BMD). Combination treatment with KK1-300 and PTH significantly decreased urinary DPD and increased serum osteocalcin, indicating a sustained beneficial effect compared to the effect of each mono-therapy. On the other hand, combination therapy with alendronate and PTH weakened the PTH-induced increase in osteocalcin. In proximal tibia, combination treatment with KK1-300 and PTH increased BMD to a level significantly higher than that achieved following single treatment with KK1-300 or PTH alone. On the other hand, combination treatment with alendronate and PTH failed to produce any significant additive effect on BMD following single treatment with alendronate or PTH alone. Microstructural analysis revealed that the PTH-induced increase in bone formation (MS/BS and BFR/BS) was fully maintained following combination treatment with KK1-300 and PTH, but not following combination treatment with alendronate and PTH. These findings indicate that KK1-300, unlike alendronate, has an additive effect on the preventive action of PTH on bone loss in OVX rats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Garnero P, Delmas PD (2004) Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 4:50–63

    PubMed  CAS  Google Scholar 

  2. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215

    Article  PubMed  CAS  Google Scholar 

  3. Amugongo SK, Yao W, Jia J, Lay YA, Dai W, Jiang L, Walsh D, Li CS, Dave NK, Olivera D, Panganiban B, Ritchie RO, Lane NE (2014) Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass. Osteoporosis Int 25:1735–1750

    Article  CAS  Google Scholar 

  4. Nishi Y, Atley L, Eyre DE, Edelson JG, Superti-Furga A, Yasuda T, Desnick RJ, Gelb BD (1999) Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res 14:1902–1908

    Article  PubMed  CAS  Google Scholar 

  5. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I (1999) Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14:1654–1663

    Article  PubMed  CAS  Google Scholar 

  6. McQueney MS, Feild J, Hanning CR, Brun K, Ramachandran K, Connor J, Drake F, Jones CS, Amegadzie BY (1998) Cynomolgus monkey (Macaca fascicularis) cathepsin K: cloning, expression, purification, and activation. Protein Expr Purif 14:387–394

    Article  PubMed  CAS  Google Scholar 

  7. Gelb BD, Shi GP, Chapman HA, Desnick RJ (1996) Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236–1238

    Article  PubMed  CAS  Google Scholar 

  8. Eastell R, Nagase S, Small M, Boonen S, Spector T, Ohyama M, Kuwayama T, Deacon S (2014) Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J Bone Miner Res 29:458–466

    Article  PubMed  CAS  Google Scholar 

  9. Williams DS, McCracken PJ, Purcell M, Pickarski M, Mathers PD et al (2013) Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate. Bone 56:489–496

    Article  PubMed  CAS  Google Scholar 

  10. Ochi Y, Yamada H, Mori H, Nakanishi Y, Nishikawa S, Kayasuga R, Kawada N, Kunishige A, Hashimoto Y, Tanaka M, Sugitani M, Kawabata K (2011) Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. Bone 49:1351–1356

    Article  PubMed  CAS  Google Scholar 

  11. Ochi Y, Kawada N, Yamada H, Mori H, Tanaka M, Hatayama A, Ohmoto K, Kawabata K (2004) Pretreatment with cathepsin K Inhibitor but not alendronate demonstrated further increases in bone mineral density in ovariectomized rats followed by add-on treatment with parathyroid hormone. J Bone Miner Res 19:S358

    Google Scholar 

  12. Iwasaki Y, Yamato H, Murayama H, Takahashi T, Ezawa I, Kurokawa K, Fukagawa M (2002) Menatetrenone prevents osteoblast dysfunction in unilateral sciatic neurectomized rats. Jpn J Pharmacol 90:88–93

    Article  PubMed  CAS  Google Scholar 

  13. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610

    Article  PubMed  CAS  Google Scholar 

  14. Yamane H, Sakai A, Mori T, Tanaka S, Moridera K, Nakamura T (2009) The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice. Bone 44:1055–1062

    Article  PubMed  CAS  Google Scholar 

  15. Ochi Y, Yamada H, Mori H, Kawada N, Kayasuga R, Nakanishi Y, Tanaka M, Imagawa A, Ohmoto K, Kawabata K (2014) ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats. J Bone Miner Metab 32:645–652

    Article  PubMed  CAS  Google Scholar 

  16. Jayakar RY, Cabal A, Szumiloski J, Sardesai S, Phillips EA, Laib A, Scott BB, Pickarski M, le Duong T, Winkelmann CT, McCracken PJ, Hargreaves R, Hangartner TN, Williams DS (2012) Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: a study with odanacatib treatment in the ovariectomized adult rhesus monkey. Bone 50:1379–1388

    Article  PubMed  CAS  Google Scholar 

  17. Jerome C, Missbach M, Gamse R (2012) Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporosis Int 23:339–349

    Article  CAS  Google Scholar 

  18. Tanaka M, Mori H, Kayasuga R, Ochi Y, Kawada N, Yamada H, Kishikawa K (2008) Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia. Bone 43:894–900

    Article  PubMed  CAS  Google Scholar 

  19. Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K (2007) Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Mineral Res 22:487–494

    Article  CAS  Google Scholar 

  20. Pennypacker B, Shea M, Liu Q, Masarachia P, Saftig P, Rodan S, Rodan G, Kimmel D (2009) Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone 44:199–207

    Article  PubMed  CAS  Google Scholar 

  21. Li CY, Jepsen KJ, Majeska RJ, Zhang J, Ni R, Gelb BD, Schaffler MB (2006) Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res 21:865–875

    Article  PubMed  CAS  Google Scholar 

  22. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metabol 85:2129–2134

    CAS  Google Scholar 

Download references

Conflict of interest

All authors have no conflicts of interest.

Author information

Authors and Affiliations

  1. Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka, 618-8585, Japan

    Yasuo Ochi, Hiroyuki Yamada, Hiroshi Mori, Naoki Kawada, Makoto Tanaka, Akira Imagawa, Kazuyuki Ohmoto & Kazuhito Kawabata

Authors
  1. Yasuo Ochi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroyuki Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroshi Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoki Kawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Makoto Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akira Imagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuyuki Ohmoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuhito Kawabata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuo Ochi.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ochi, Y., Yamada, H., Mori, H. et al. Combination therapy with ONO-KK1-300-01, a cathepsin K inhibitor, and parathyroid hormone results in additive beneficial effect on bone mineral density in ovariectomized rats. J Bone Miner Metab 34, 33–40 (2016). https://doi.org/10.1007/s00774-014-0643-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-014-0643-1

Keywords

Search

Navigation